Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

05 Mar 2017 - 09 Mar 2017
20 Mar 2017 - 23 Mar 2017
12 Apr 2017 - 14 Apr 2017

Adipose-Derived Stem Cells Are More Potent Immunomodulators Than Those Derived from Bone Marrow

By BiotechDaily International staff writers
Posted on 04 Jun 2013
ADVERTISEMENT
SARTORIUS AG
A recent paper revealed that stem cells derived from fat (adipose) tissue were more potent than those originating from bone marrow as modulators of the body’s immune system.

Considering that adipose tissue-derived stem cells (AT-SCs) are far more plentiful in the body than those found in bone marrow (BM-MSCs), the findings reported by investigators at the Leiden University Medical Center (The Netherlands) should prompt further research into the use of AT-SCs in personalized immunomodulatory therapy.

The investigators compared the immunomodulatory capacities of BM-MSCs and AT-MSCs derived from age-matched donors. They reported in the May 21, 2013, online edition of the journal STEM CELLS Translational Medicine that BM-MSCs and AT-MSCs shared a similar immunophenotype and capacity for in vitro multilineage differentiation.

BM-MSCs and AT-MSCs showed comparable immunomodulatory effects as they were both able to suppress proliferation of stimulated peripheral blood mononuclear cells and to inhibit differentiation of monocyte-derived immature dendritic cells. However, at equal cell numbers, the AT-MSCs showed more potent immunomodulatory effects in both assays as compared with BM-MSCs. Moreover, AT-MSCs showed a higher level of secretion of cytokines that have been implicated in the immunomodulatory modes of action of multipotent stromal cells, such as interleukin-6 and transforming growth factor-beta-1 (TGF-beta-1).

AT-MSCs displayed higher metabolic activity than BM-MSCs, which meant that lower numbers of AT-MSCs could evoke the same level of immunomodulation as higher numbers of BM-MSCs.





Channels

Drug Discovery

view channel
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).

Experimental Drug Slows Lung Cancer Growth by Blocking Protein Glycosylation

An interesting new experimental anti-cancer drug slows growth of certain lung tumor cells by preventing the glycosylation of critical cell surface receptor proteins. Asparagine (N)-linked glycosylation... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.